Anti-Inflammatory drug may boost cancer therapy in bile duct cancer

NCT ID NCT07632235

Recruiting now Disease control Sponsor: Shanghai 6th People's Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding the anti-inflammatory drug celecoxib to standard immunotherapy and chemotherapy can help people with advanced bile duct cancer live longer without their disease getting worse. The trial focuses on patients whose tumors have high levels of a marker called CK5/6. About 112 participants will be randomly assigned to receive either the standard treatment or the standard treatment plus celecoxib. The study is currently recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: celecoxib (an anti-inflammatory drug) plus pembrolizumab (immunotherapy) and gemcitabine/cisplatin (chemotherapy)
What this could lead to: If successful, this could offer a more effective, personalized treatment option for people with a specific type of advanced bile duct cancer.
What could go wrong: This is an early-phase trial with a small number of participants. Adding celecoxib may not improve outcomes and could increase side effects like kidney or heart problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INTRAHEPATIC CHOLANGIOCARCINOMA (ICC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cholangiocarcinoma Cirrhosis, Familial, with Pulmonary Hypertension intrahepatic cholangiocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INTRAHEPATIC CHOLANGIOCARCINOMA (ICC)

Contacts and locations

Locations

Renji Hospital
RECRUITING

Shanghai, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.